A Case of Pyrazinamide Induced Fulminant Hepatic Failure.
10.4046/trd.2007.63.5.435
- Author:
Dae Sung MOON
1
;
Tae Won JANG
;
Chul Ho OAK
;
Maan Hong JUNG
;
Chan Hui YOO
;
Jun Young SONG
;
Sung Eun KIM
;
Ja Kyung KIM
;
Lee La JANG
;
Eun Young LEE
;
Gyu Sik JUNG
Author Information
1. Department of Internal Medicine, College of Medicine, Kosin University, Busan, Korea. jangtw@ns.kosinmed.or.kr
- Publication Type:Case Report
- Keywords:
Drug induced hepatitis;
Fulminant hepatic failure;
Pyrazinamide
- MeSH:
Drug-Induced Liver Injury;
Ethambutol;
Incidence;
Isoniazid;
Liver;
Liver Failure, Acute*;
Pyrazinamide*;
Rifampin;
Tuberculosis
- From:Tuberculosis and Respiratory Diseases
2007;63(5):435-439
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Standard antituberculous therapy, including isoniazid (INH), rifampin, ethambutol, and pyrazinamide (PZA), is widely used to treat active tuberculosis. The most important side effect is hepatotoxicity. In a standard four-drug regimen, PZA was the most common cause of drug-induced hepatitis and was dose-related. The incidence of drug-induced hepatitis is high at doses of 40~70 mg/kg per day but has fallen significantly since the recommended dose was reduced. Liver toxicity induced by PZA is rare at doses of 25 mg/kg per day or less. PZA-induced fulminant hepatic failure is also rare but fatal. We report a case of fulminant hepatic failure caused by a re-challenge of PZA.
